FDA Accepts Supplement Application for Tyvaso (Treprostinil)
The FDA has accepted a supplemental application for Tyvaso, an inhaled formulation of treprostinil.
Therapeutic Area
Therapeutic area intelligence for Pulmonary Arterial Hypertension with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.